The leader of drug maker Moderna says the company should know in November whether its experimental COVID-19 vaccine works. Stephane Bancel spoke on the financial news network CNBC Thursday, the same day Moderna released a document that details its vaccine trial plans. Bancel told Reuters that if its COVID-19 vaccine proves to be at least 70 percent effective, the company would seek Emergency Use Authorization (EUA) for people in high-risk groups. The high-risk groups would include healthcare workers and older people. U.S. government officials say a vaccine candidate must show it is at least 50 percent more effective than a placebo, before the Food and Drug Administration (FDA) would consider it for approval. Moderna, based in Massachusetts, has never brought a vaccine to market. But the U.S. government’s Operation Warp Speed program has given the company almost $1 billion for its work on a vaccine. Moderna has a $1.5 billion agreement with the U.S. to supply COVID-19 vaccine.